人福医药：关于玉蚕颗粒进入Ⅱ期临床试验研究的公告

Core Viewpoint - The company announced that its wholly-owned subsidiary, Wuhan Renfu Innovative Drug Research and Development Center Co., Ltd., has registered Phase II clinical trial information on the National Medical Products Administration's platform [2] Group 1 - The announcement was made on the evening of September 9 [2] - The registration of the clinical trial is a significant step in the drug development process [2] - The information is publicly available on the drug clinical trial registration and information disclosure platform [2]